Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 12/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 11/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099885 | 1.00 | PTGER4 (0.45) | PTGER4PTGER2PTGER3TBXA2RPTGER1 | |
| SCHEMBL4299817 | 0.92 | PTGER4 (0.46) | PTGER4PTGER2PTGER3TBXA2RPTGER1 | |
| SCHEMBL4088157 | 0.92 | PTGER4 (0.46) | PTGER4PTGER2PTGER3TBXA2RPTGER1 | |
| SCHEMBL4078893 | 0.91 | PTGER4 (0.49) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4299062 | 0.91 | PTGER4 (0.49) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL3984251 | 0.89 | PTGER4 (0.35) | PTGER4PTGER2PTGER3TBXA2RPTGER1 | |
| SCHEMBL4300863 | 0.89 | PTGER4 (0.35) | PTGER4PTGER2PTGER3TBXA2RPTGER1 | |
| SCHEMBL3982417 | 0.88 | PTGER4 (0.43) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4078854 | 0.86 | PTGER4 (0.47) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4258218 | 0.86 | PTGER4 (0.47) | PTGER4PTGER2PTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-10-29 | — | — | US | claimed |
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.